

11 December 2025

**Physiomics plc**  
**("Physiomics" or the "Company")**

**Physiomics Awarded New Contract by Numab Therapeutics**

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG.

This latest project will use modelling and simulation approaches to support the pre-clinical development of a multi-specific antibody in the Numab Therapeutics pipeline, under development for the treatment of autoimmune diseases. In this collaboration, Physiomics will develop a mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) model that can be used to inform quantitative understanding of the drug's behaviour and select appropriate dosing for preclinical and clinical studies. The project is expected to be delivered within the financial year ending 2026.

This new contract further emphasises the important role that Model Informed Drug Development approaches continues to play across the drug development lifecycle, including in the pre-clinical environment.

**Dr Peter Sargent, CEO of Physiomics, commented:**

*"We are very pleased to announce a further contract with Numab Therapeutics, one of our most valued clients, and continue to support the development of their pipeline of therapeutic antibodies across both Oncology and Autoimmune indications."*

For more information about Physiomics and its services, please visit [www.physiomics.co.uk](http://www.physiomics.co.uk).

**Enquiries:**

**Physiomics plc**

Dr Peter Sargent, CEO  
+44 (0)1235 841575

**Hybridan LLP (Broker)**

Claire Louise Noyce  
+44 (0) 203 764 2341

**Strand Hanson Ltd (NOMAD)**

James Dance & James Bellman  
+44 (0)20 7409 3494

**Notes to Editor**

**About Physiomics**

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTVBLFFELLBFBV